Mavenclad
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Cladribine
- Made by
- Merck Europe B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Cladribine). It describes the substance, not this exact product.
The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes.
After administration of 10 mg oral cladribine in MS patients, 28.5 [20] (mean [SD]) percent of the dose was excreted unchanged via the renal route.
Effect of Food Following administration of cladribine with a high fat meal, the geometric mean C max decreased by 29% and AUC was unchanged.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-19
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Merck Europe B.V. |
|---|---|
| Active substance | Cladribine |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L04AA40 · Cancer treatments and immune-system medicines |
| Authorised on | 2017-08-22 |
| Last updated by the regulator | 2026-01-13 |
| EMA product number | EMEA/H/C/004230 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.